Skip to search formSkip to main contentSkip to account menu

Cyclosporine Ophthalmic Suspension [Restasis]

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AIM To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1… 
2017
2017
Purpose Aging is an important factor in dry-eye disease that has not been studied in the context of therapeutic measures. Aging… 
2016
2016
PurposeCyclosporine A (Cs) has been used as effective topical therapy for inflammatory dry eye disease since more than a decade… 
2014
2014
Background The objective of this study was to compare the efficacy of cyclosporin (CsA)-encapsulated liposomes with the… 
2013
2013
A lot of researches have investigated the effects of topical cyclosporine A on the eye surface layers’ diseases. By now the main… 
Highly Cited
2011
Highly Cited
2011
PURPOSE This retrospective, clinical comparative analysis describes differences in clinical signs and symptoms and medication… 
Highly Cited
2011
Highly Cited
2011
  • C. GuptaA. Chauhan
  • Journal of controlled release : official journal…
  • 2011
  • Corpus ID: 36260514
2008
2008
Purpose: We conducted a study to evaluate the change of tear secretion and symptoms in the patients with dry eye syndrome after…